4.8 Article

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 383, 期 16, 页码 1544-1555

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa2024671

关键词

-

资金

  1. Intramural Research Program of the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
  2. Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, Department of Health and Human Services [75A50120C00034]
  3. Undergraduate Scholarship Program, Office of Intramural Training and Education, Office of the Director, NIH
  4. NIAID [T32-AI007151, F32 AI152296]
  5. Burroughs Wellcome Fund Postdoctoral Enrichment Program Award
  6. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005125, ZICAI005162, ZIAAI005149, ZICAI005111, ZIAAI005147, ZIAAI005159, ZICAI005164, ZIAAI005152, ZIAAI005150, ZIAAI005047, ZIGAI005158] Funding Source: NIH RePORTER

向作者/读者索取更多资源

BackgroundVaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. MethodsNonhuman primates received 10 or 100 mu g of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens. ResultsThe mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID50) geometric mean titers of 501 in the 10-mu g dose group and 3481 in the 100-mu g dose group. Vaccination induced type 1 helper T-cell (Th1)-biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100-mu g dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group. ConclusionsVaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.) Two injections of an mRNA-based vaccine encoding the SARS-CoV-2 spike protein elicited high levels of neutralizing antibody and Th1 CD4 T-cell responses in rhesus macaques. Two days after challenge of vaccinated animals with intranasal and intratracheal virus, viral replication was undetectable in bronchoalveolar-lavage fluid and nasal secretions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据